AxoSim empowers advancements in human neuroscience and accelerates the drug development process through our drug discovery platforms, NerveSim™ and BrainSim™
Learn More
Our technology enables researchers to predict human outcomes in the lab. We deliver accurate preclinical testing to help develop safer, more effective drugs.
Almost 90% of drugs that look promising in animal models fail when tested in humans, driving up the average cost and time of new drug development to $2.6 billion and 10 years or more. We deliver predictive human data in just weeks and at a fraction of the cost of in vivo studies.
Achieve the predictive readouts critical to your R&D success. We deliver clinically-relevant functional and structural metrics to improve success rates.
AxoSim's NerveSim™ Platform, powered by Nerve-on-a-Chip® facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
BrainSim™ is a high quality 3D miniature brain organoid designed to serve as a human-relevant model in preclinical drug discovery.
On Wednesday, September 30th, AxoSim Lead Scientist, Anup Sharma, PhD, spoke at our interactive webinar: Human Schwann Cells: Importance for Peripheral Neuropathy […]
Read MoreHigh Throughput, Human Data: AxoSim’s Human Peripheral Co-Culture Assay In addition to our 3D NerveSim™ and BrainSim™ models, AxoSim also performs a […]
Read MoreIntroducing our newest SimLab Service: Human Co-Culture Peripheral Assay We are excited to launch our newest assay which uses human Schwann cells […]
Read MoreOn Wednesday, September 16th at 11:00am EST, AxoSim CEO, Dr. Lowry Curley will be giving a dynamic poster presentation at Safety Pharmacology […]
Read More
